MIR625 (MicroRNA 625)

News alerts, weekly reports and conference planners

Entrez ID:

miR-625-5p underexpression + PD-L1 overexpression	Non Small Cell Lung Cancer	miR-625-5p underexpression + PD-L1 overexpression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
miR-625-5p underexpression + PD-L1 overexpression	Non Small Cell Lung Cancer	miR-625-5p underexpression + PD-L1 overexpression	Non Small Cell Lung Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
miR‑625‑3p overexpression	Non Small Cell Lung Cancer	miR‑625‑3p overexpression	Non Small Cell Lung Cancer	gefitinib Resistant: D – Preclinical gefitinib Resistant : D	gefitinib Resistant: D – Preclinical gefitinib Resistant : D

Associations(3)